Functional characterization of fibrinogen Bicêtre II: a gamma 308 Asn-->Lys mutation located near the fibrin D:D interaction sites.
The effects of the gamma-308 Asn-->Lys substitution of fibrinogen Bicêtre II on clot formation, structure and properties were determined to elucidate the role of this part of the molecule in fibrin polymerization. This process was followed by measurement of turbidity, and the structure and biophysical characteristics of the clots were studied by permeation, scanning electron microscopy, and rheological techniques. Turbidity studies revealed an increased lag period and greater final turbidity for fibrin BII clots, indicating impaired oligomer formation. By permeation it was found that BII clots had greater network porosity, four times more than that of the control. The clot architecture visualized by scanning electron microscopy was similar to that of control clots with pore size and fiber diameter slightly increased. BII clots had a stiffness decreased by more than half, and an increased loss tangent, a measure of the inelastic deformation of the clot. All these results suggest a disruption of the proper alignment of fibrin monomers during oligomer formation. Consistent with these results, fibrin cross-linking by adding the physiological concentration of factor XIII to the purified protein showed that gamma and alpha chain cross-linking was impaired in BII clots. This amino acid substitution defines distinctive effects on the surface of the D:D interaction sites that are reflected in the clot structure and functional properties.
Department of Cell and Developmental Biology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA.
Rita C
RC
Marchi
Zoila
Z
Carvajal
Catherine
C
Boyer-Neumann
Eduardo
E
Anglés-Cano
John W
JW
Weisel
D000328:Adult; D001216:Asparagine / Q000235:genetics; D001777:Blood Coagulation / Q000235:genetics*; D020147:Coagulation Protein Disorders / Q000209:etiology / Q000235:genetics*; D005176:Factor XIII / Q000378:metabolism; D005337:Fibrin / Q000737:chemistry / Q000235:genetics / Q000648:ultrastructure; D005338:Fibrin Fibrinogen Degradation Products / Q000235:genetics*; D015241:Fibrinogens, Abnormal / Q000235:genetics* / Q000378:metabolism* / Q000502:physiology; D005342:Fibrinolysis / Q000235:genetics; D006801:Humans; D008239:Lysine / Q000235:genetics; D008297:Male; D008855:Microscopy, Electron, Scanning; D008958:Models, Molecular; D020125:Mutation, Missense / Q000235:genetics*; D012016:Reference Values
D005338:Fibrin Fibrinogen Degradation Products; D015241:Fibrinogens, Abnormal; C036309:fibrin fragment D; C085517:fibrinogen Bicetre II; D001216:Asparagine; D005337:Fibrin; D005176:Factor XIII; D008239:Lysine